UNSPSC 51143005: Brivaracetam

This classification denotes a neuroprotective agent and anticonvulsant agent with the molecular formula C11H20N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, U863JGG2IA chemically known as 1-pyrrolidineacetamide, .alpha.-ethyl-2-oxo-4-propyl (.alpha.s,4r)- but generally known as brivaracetam, which bears US NIH Compound Identifier 9837243. European Medicines Agency schedules Brivaracetam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25397.

UNSPSC 51143005 Brivaracetam is a Commodity code for a single pharmaceutical product — an antiepileptic medication used to treat partial-onset seizures in patients with epilepsy. State and local governments procure brivaracetam primarily through Medicaid programs, corrections departments, and state health agencies that serve institutionalized or insured populations. The code reflects a narrow therapeutic category where procurement is driven by formulary decisions, clinical protocols, and population health mandates rather than competitive bid cycles typical of broader drug families.

The source provides no recent state and local contract opportunities under this code, indicating minimal or no active solicitation activity at the state, county, municipal, or special-purpose district level during the current procurement window. Brivaracetam procurement, when it occurs, is likely managed through existing pharmaceutical supply contracts, group purchasing agreements, or standing Medicaid drug formularies rather than discrete RFPs, RFQs, or ITBs.